Investigational drug · Phase 3
Quemliclustat
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Non-Small Cell Lung Cancer, Gastrointestinal Tract Malignancies.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
14
Any phase or sponsor naming "Quemliclustat"
First trial start
2022
Jun 10, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Quemliclustat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Pancreatic Ductal Adenocarcinoma
- Advanced Non-Small Cell Lung Cancer
- Gastrointestinal Tract Malignancies
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Quemliclustat" as an intervention, largest first.
- Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaPivotal-lookingActive, not recruiting
Arcus Biosciences, Inc.Industry
NCT06608927 · 610 participants (planned) · Start Dec 13, 2024 · Primary completion Nov 30, 2030
Drug: Quemliclustat; Placebo and 2 more · For: Metastatic Pancreatic Ductal Adenocarcinoma
Sites: Phoenix, Arizona; Tucson, Arizona; La Jolla, California · 111 sites in all
- Study With Various Immunotherapy Treatments in Participants With Lung CancerPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05676931 · 400 participants (planned) · Start Feb 21, 2023 · Primary completion Dec 2027
Drug: Domvanalimab; Quemliclustat and 3 more · For: Advanced Non-Small Cell Lung Cancer
Sites: Birmingham, Alabama; La Jolla, California; Hollywood, Florida · 53 sites in all
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT05329766 · 332 participants · Start Jun 10, 2022 · Primary completion Sep 7, 2026
Drug: Domvanalimab; Quemliclustat and 4 more · For: Gastrointestinal Tract Malignancies
Sites: Phoenix, Arizona; Los Angeles, California; Santa Monica, California · 43 sites in all
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.Pivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04660812 · 227 participants · Start May 10, 2021 · Primary completion Sep 5, 2025
Drug: AB680; Etrumadenant and 4 more · For: Metastatic Colorectal Cancer
Sites: Tucson, Arizona; Duarte, California; Santa Monica, California · 44 sites in all
- A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal MalignanciesPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04104672 · 196 participants · Start Nov 6, 2019 · Primary completion Jul 21, 2026
Drug: AB680; Zimberelimab and 2 more · For: Advanced Pancreatic Cancer
Sites: Santa Monica, California; St Louis, Missouri; New York, New York · 9 sites in all
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04381832 · 173 participants · Start Jul 7, 2020 · Primary completion Aug 30, 2024
Drug: Etrumadenant; Zimberelimab and 4 more · For: Prostatic Neoplasms, Castration-Resistant; Androgen-Resistant Prostatic Neoplasms; Castration Resistant Prostatic Neoplasms and 1 more
Sites: Cerritos, California; Encino, California; Orange, California · 19 sites in all
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT05688215 · 141 participants (planned) · Start Mar 7, 2023 · Primary completion Dec 31, 2027
Drug: Fluorouracil; Irinotecan and 5 more · For: Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma
Sites: Los Angeles, California
Arcus Biosciences, Inc.Industry
NCT03677973 · 64 participants · Start Oct 16, 2018 · Primary completion Aug 19, 2019
Drug: AB680 · For: Healthy Volunteers
Sites: Melbourne, Australia
Gulam ManjiAcademic, hospital or other
NCT06048484 · 60 participants (planned) · Start May 10, 2024 · Primary completion Apr 2027
Drug: Zimberelimab; Quemliclustat and 2 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Lake Success, New York; New York, New York; Chapel Hill, North Carolina · 5 sites in all
- Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Active, not recruiting
Nataliya UbohaAcademic, hospital or other
NCT06048133 · 33 participants (planned) · Start Mar 8, 2024 · Primary completion Dec 2026
Drug: Gemcitabine; Cisplatin and 2 more · For: Biliary Tract Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Sites: Indianapolis, Indiana; Ann Arbor, Michigan; New Brunswick, New Jersey · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Oncogenic KRAS-MAPK signaling sustains a CD73 dependent therapeutic vulnerability in pancreatic cancer.
Turabi K, Sardarni UK, Ankenbauer KE, et al. · bioRxiv 2026
- Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Wainberg ZA, Manji GA, Bahary N, et al. · Nat Med 2026
- Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
Piovesan D, Tan JBL, Becker A, et al. · Mol Cancer Ther 2022
Also in development for Metastatic Pancreatic Ductal Adenocarcinoma
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- ChiauranibCS2164Phase 33 trials
Chipscreen Biosciences, Ltd. · Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
- TQB2868Phase 32 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Pancreatic Neoplasms, Metastatic Pancreatic Ductal Adenocarcinoma
- ponsegromabPhase 31 trial
Pfizer · Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
- BotensilimabAGEN1181, 8541APhase 24 trials
Agenus Inc. · Metastatic Colorectal Cancer, Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), Untreated
- JAB-23E73Phase 23 trials
Jacobio Pharmaceuticals Co., Ltd. · Advanced Solid Tumor, Advanced Solid Tumors, Metastatic Pancreatic Ductal Adenocarcinoma
- RMC-9805Phase 23 trials
Revolution Medicines, Inc. · PDAC, Colorectal Cancer, CRC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.